Cilgavimab/Tixagevimab
Cilgavimab/Tixagevimab is a combination of two monoclonal antibodies designed for the prevention and treatment of COVID-19. This combination is developed by AstraZeneca, a British-Swedish multinational pharmaceutical and biopharmaceutical company.
Mechanism of Action[edit | edit source]
Cilgavimab and Tixagevimab work together to bind to different sites on the spike protein of the SARS-CoV-2 virus, preventing the virus from entering human cells. This dual action is believed to increase the effectiveness of the treatment and reduce the likelihood of the virus developing resistance.
Clinical Trials[edit | edit source]
The combination of Cilgavimab and Tixagevimab has been tested in several clinical trials. In the Phase III trials, the combination was shown to reduce the risk of severe COVID-19 and death in high-risk patients.
Approval[edit | edit source]
As of February 2022, Cilgavimab/Tixagevimab has been granted emergency use authorization by the U.S. Food and Drug Administration (FDA) and conditional marketing authorization by the European Medicines Agency (EMA).
Side Effects[edit | edit source]
Common side effects of Cilgavimab/Tixagevimab include nausea, vomiting, diarrhea, and fever. Serious side effects are rare but can include severe allergic reactions.
See Also[edit | edit source]
References[edit | edit source]
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD